# Rock Springs Capital

> Rock Springs Capital is a VC fund backing Biotechnology and Health Care. See 162 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Baltimore, United States
- Total investments: 162
- Last investment: Jun 2026
- Lead investor: 6%
- Fund size: $1.1B
- Last fund: Oct 2017
- Last updated: Aug 2026
- Website: http://rockspringscapital.com

Rock Springs Capital is an investment company located in Baltimore, Maryland. Its advisory activities include management services to security portfolios and portfolio management for businesses or institutional clients.

## Contacts

5 contacts available for Rock Springs Capital. Shizune tracks 1 team members at Rock Springs Capital. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/rock-springs-capital?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 107 | 66% |
| Health Care | 63 | 39% |
| Medical | 49 | 30% |
| Therapeutics | 48 | 30% |
| Pharmaceutical | 45 | 28% |

33 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 44 | 27% |
| Series C | 33 | 20% |
| Post-IPO Equity | 22 | 14% |
| Series A | 11 | 7% |
| Series D | 11 | 7% |

11 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 101 | 62% |
| China | 5 | 3% |
| Canada | 3 | 2% |
| United Kingdom | 2 | 1% |
| France | 1 | 1% |

12 countries tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Kris Jenner | Partner | 6 | https://shizune.co/investors/profile/kris-jenner-08cb |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| City Therapeutics | City Therapeutics is a biopharmaceutical company focusing on engineering next-generation small-interfering RNAs (siRNAs) to enhance RNAi-based therapies. The company develops a pipeline of innovative RNAi therapeutics aimed at addressing various disease indications. City Therapeutics prioritizes improving and expanding RNAi technology to achievebetter patient outcomes. The leadership team includes experienced scientists and industry professionals dedicated to advancing the field of RNA interference. | $99.5M | Series B | Jun 08, 2026 |  |
| Parabilis Medicines | Parabilis Medicines is a biopharmaceutical company in the clinical stage that focuses on developing exceptional medications targeting challenging protein structures previously deemed undruggable. Utilizing more than ten years of exclusive data, innovative laboratory techniques, and algorithms based on AI and physics, the company has introduced anovel category of stabilized, cell-penetrating alpha-helical peptides known as Helicons™. These peptides can modulate intracellular proteins that traditional drug modalities cannot reach. | $305M | Series F | Jan 08, 2026 |  |
| Hemab | Hemab is a company that creates preventative treatments for bleeding and thrombosis problems. The medicines developed by the business aggregate modify, balance, and at times recruit endogenous clotting components already present in the blood to the site of injury, allowing patients to produce hemostatic plugs or clots to avert life-threateningcomplications. | $157M | Series C | Oct 27, 2025 |  |
| Talphera | AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of pain and other conditions. It offers NanoTab, a tablet for oral transmucosal administration. The company also provides Sufentanil NanoTab PCA system, a sublingual patient-controlled analgesia systemwith a drug/device combination product candidate for the management of acute post-operative pain in the hospital settings; Sufentanil NanoTab BTP management systems for the treatment option for patients with cancer pain; and Sufentanil/Triazolam NanoTab, which provides analgesia and sedation for minor outpatient procedures. It serves patients, physicians, regulators, and payers. AcelRx Pharmaceuticals, Inc. was founded in 2005 and is based in Redwood City, California. | $17M | Post-IPO Equity | Sep 08, 2025 |  |
| Treeline Biosciences | Treeline Biosciences is a biotech company building transformative precision medicines for patients with cancer and other serious conditions. The company was founded in 2021 and is headquartered in Stamford, CT. | $200M | Series A | Sep 03, 2025 |  |
| Avalyn Pharma | Avalyn Pharma is a biopharma company that advances therapies for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and other severe respiratory diseases. Its therapies rapidly advance AP01 for the treatment of IPF, provides additional pipeline candidates for IPF, improve the care and outcomes of severe respiratory diseases, and develop novelinhaled therapeutics.Avalyn Pharma was established in 2011 and is headquartered in Seattle, Washington. | $100M | Series D | Jul 22, 2025 |  |
| Latigo Biotherapeutics | Operator of a drug discovery company intended to develop novel, non-opioid therapies for chronic pain. The company utilizes unique, translated insights to provide a differentiated approach to targeting therapeutics across the blood-nerve barrier, enabling patients to get access to a pain management therapy that does not create addiction, dependenceor tolerability. | $150M | Series B | Mar 17, 2025 |  |
| Aclaris Therapeutics | Aclaris Therapeutics started by the founders of Vicept Therapeutics, is a privately held specialty pharmaceutical dermatology company focused on the development of novel dermatologic therapies. It is committed to identifying, developing, and commercializing innovative therapies to address significant unmet needs in dermatology, both medical andaesthetic, and immunology. Aclaris is focused on market segments with no FDA-approved medications or where treatment gaps exist. | $80M | Post-IPO Equity | Nov 18, 2024 |  |
| City Therapeutics | City Therapeutics is a biopharmaceutical company focusing on engineering next-generation small-interfering RNAs (siRNAs) to enhance RNAi-based therapies. The company develops a pipeline of innovative RNAi therapeutics aimed at addressing various disease indications. City Therapeutics prioritizes improving and expanding RNAi technology to achievebetter patient outcomes. The leadership team includes experienced scientists and industry professionals dedicated to advancing the field of RNA interference. | $135M | Series A | Oct 08, 2024 |  |
| ArsenalBio | ArsenalBio is building a programmable cell therapy company to create highly effective and accessible immune cell therapies to impact outcomes for a much broader number of patients, initially those with cancer. Founded in 2019, ArsenalBio is focused on integrating technologies such as CRISPR-based genome engineering, scaled and high throughputtarget identification, synthetic biology, and machine learning to advance a new paradigm to discover and develop immune cell therapies. With its programmable and computationally driven approach, ArsenalBio aspires to evolve critical metrics of success for immune cell therapies, including enhanced and broader efficacy, increased patient safety, reduced provider costs and expanded market access. | $325M | Series C | Sep 04, 2024 |  |

10 of 162 investments shown.

## Co-investors
- [RA Capital Management](https://shizune.co/investors/profile/ra-capital-management) — VC Fund, 35 deals together
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund, 29 deals together
- [T. Rowe Price](https://shizune.co/investors/profile/t-rowe-price) — VC Fund, 29 deals together
- [Perceptive Advisors](https://shizune.co/investors/profile/perceptive-advisors) — VC Fund, 25 deals together
- [Janus Henderson Investors](https://shizune.co/investors/profile/janus-henderson-investors) — VC Fund, 23 deals together
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund, 22 deals together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Rock Springs Capital invest in?

Rock Springs Capital invests primarily in Biotechnology, Health Care and Medical startups, most often at Series B and Series C stage. Most of the 162 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Rock Springs Capital?

Public channels for Rock Springs Capital include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Rock Springs Capital?

The team at Rock Springs Capital includes Kris Jenner (Partner). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co